TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Mean FeNO Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive MCC Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for FeNO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Ventricular systolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Change in Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diagnostic accuracy of ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Hyperintense Acute injuRy Marker (HARM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Intracerebral Hemorrhage (ICH) Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nosocomial MRSA isolation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: red blood cell folate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Induction of peptide-specific T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Successful Tissue Expansion and Exchange to Permanent Breast Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Appendicular Lean Body Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mineral Change (delta Z)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of anxiety and/or depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Keratometric indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant Vital sign abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant physical examination abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant haematology assessment abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant serum chemistry assessment abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with clinically significant urinalysis assessment abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Family asthma management system scale (FAMSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diaphragmatic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodic memory performance - learning curve
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Episodic memory performance - delayed recall 1
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Episodic memory performance - delayed recall 2
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline of Sino-Nasal Outcome Test (SNOT-22) Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Concentration-time Curve (AUC) from Time Zero to Infinite Time (AUC[0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Weekly Mean Pain Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postabortal inflammatory disease
Endpoint domain: Adverse events/effects
Primary endpoint: clinical healing of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary concentration of alpha-ketoglutarate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasmatic and urinary pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Nasal resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The number of participants with an adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Expired-air Carbon Monoxide Confirmed Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Composite Stress Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to 12 Weeks in Individual Scaled Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interproximal Mean Plaque Index at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole-mouth Mean Plaque Index at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life measure
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Species diversity in fecal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 years recurrence-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in adventitious lung sounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Financial health measure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Use of allogenic banked blood products
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Economic cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cmax for Methadone, buprenorphine, and norbuprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(TAU) for Methadone, buprenorphine, and norbuprenorphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HF patients revisited emergency department
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: autoantigen-specific T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: leukocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Daily Average Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in sputum colony forming unit (CFU) counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Recurrent thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in systolic arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum levels of IL4, IL10, IFN γ, IL2, IL12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PBMC supernatant levels of IL4, IL10, IFN γ, IL2, IL12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Head and Neck Cancer Survivor Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Stroke Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of research ideas generated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pertinence of research ideas generated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Total Lesion Symptom Score (TLSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean internal knee extension moment during landing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean internal hip flexion moment during landing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak vertical ground reaction force during landing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak vertical ground reaction force loading rate during landing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean peak patellar tendon force during landing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of Pregnancy-associated Hypertension and Serious Adverse Outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Severe Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fetal Death After 20 Weeks of Gestation or Neonatal Death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients Receiving Radiosurgery/SBRT Per Protocol or With Minor Variation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Patients With Complete or Partial Pain Response at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burnout Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Adverse Events (AEs) and AEs of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Laboratory Abnormalities Based on Hematology, Blood Chemistry, Coagulation, and Urinalysis Test Results
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Electrocardiogram (ECG) Abnormalities Based on ECG Interpretation
Endpoint domain: Adverse events/effects
Primary endpoint: Aachener Aphasia Test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Oxford Cognitive Screen score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with a Major vascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Still Receiving Therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in 400 UI of vitamin D2 over 25-Hydroxy Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 800 UI of vitamin D2 over 25-Hydroxy Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 1000 UI of vitamin D3 over 25-Hydroxy Vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Drug Urinalysis Screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV/STI risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Non-inferiority of Anti-VEGF treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper airway elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peripheral intravenous catheter patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine Iodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Free Survival at 1 Year Post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Change in Six-Minute Walk Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Type 2 Myofiber Cross Sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: decrease in antibody reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting Adverse Events (AEs), by Severity Grade
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Adverse Events (AEs), by Relationship to Study Product
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary N-acetyl-beta-D-glucosaminidase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary Kidney Injury Molecule -1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary Neutrophil gelatinase-associated lipocalin (NGAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary biomarkers of predisposition to kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Dimebon area under the curve from 0 to the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dimebon area under the curve from 0 to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing a Clinically Significant Renal, Cardiac or Cerebrovascular Event and/or Death
Endpoint domain: Mortality/survival
Primary endpoint: Change in Growth hormone (GH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in insulin-like growth factor-1 (IGF-1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum tolerated dose (MTD) of ABT-888
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18F NaF-PET/CT uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Without Recurrent Clinical Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: tumor assessment in millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of participants with seroconversion against YF antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in assessment of intensity of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of tolerability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: neuropsychological test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Adverse events/effects
Primary endpoint: Toxicities of Aerosol Gemcitabine (GCB)
Endpoint domain: Adverse events/effects
Primary endpoint: MRCP quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of Parkinson's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination of knee giving-way
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increase in HbA1c by 0.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Preliminary Safety (device- and procedure-related SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Expenditure on material supplies and medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neuropathic Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early detection of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Local progression-free interval
Endpoint domain: Mortality/survival
Primary endpoint: Inhibition of structural damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median monthly seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Rates of toxicity (breast edema/pain, hyperpigmentation, erythema)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Shear Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibody Dependent Cell-mediated Cytotoxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Motor/Language (ML) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunogenicity of BMN 190 in CSF and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of subjects with drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-tz (area under the concentration-time curve of BI 1569912 in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (maximum measured concentration of BI 1569912 in plasma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission of acute charcot
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration at steady state (Cmax,ss) of HL237
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve during a dosage interval (AUCτ) of HL237
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak whole-blood concentration (Cmax) of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the whole-blood concentration versus time curve from time zero to time of last measurable concentration (AUClast) of tacrolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Evaluable fMRI Scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medication-related problems per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of HbA1c at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of fasting plasma glucose (FPG) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of postprandial plasma glucose (PPG) at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adipogenesis of adipose-derived stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outcome of repeat biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: EORTC QLQ-C30 symptom summary score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma concentration of Metoprolol and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of pulmonary embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean cumulative irritation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to complete study in operating room and ICU
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Colorectal Cancer Screening Participation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bleeding duration 60mg edoxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding volume 60mg edoxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding duration 180mg edoxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding volume 180mg edoxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound Hyperalgesia Index (WHA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with sensorineural hearing loss
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of radial occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tumor genetic sequence variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of HemoSpec for the diagnosis of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Curve (AUC) of Dutasteride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of Tadalafil, Dutasteride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue transglutaminase autoantibodies (tTGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in VAS Anxiety Score Relative to Baseline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time between planning of Radiation treatment and the start of radiotherapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: The effect of breathing on the position of the heart and lung in treatment plans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of coronary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of perioperative hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detected volume measured by SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes